The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Blood Cancers Today Staff WritersMyeloma | September 21, 2023
The phase III study included patients who received at least one prior line of therapy.
Read More
Blood Cancers Today Staff WritersMyeloma | September 21, 2023
The researchers sought to assess the utility of MRD outside the context of clinical trials.
Blood Cancers Today Staff WritersMyeloma | September 21, 2023
Daratumumab in combination with lenalidomide and dexamethasone provided greater OS in most subgroups.
Leah LawrenceLatest Issue | September 20, 2023
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Thomas Martin, MDVideo Insights | September 19, 2023
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
Sagar Lonial, MD, FACPVideo Insights | September 19, 2023
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
Cecilia BrownMyeloma | September 4, 2023
Researchers examined tumor-intrinsic factors that promote multiple myeloma antigen escape.
Ajay Nooka, MD, FACPMyeloma | August 28, 2023
Ajay Nooka, MD, FACP, discusses the data behind the FDA accelerated approval of elranatamab.
Cecilia BrownMyeloma | August 21, 2023
Dr. Nooka, who served as an investigator on the MagnetisMM-3 trial, discusses the impact of the accelerated approval.
Cecilia BrownMyeloma | August 21, 2023
CART-ddBCMA is an investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma.
Cecilia BrownMyeloma | August 16, 2023
There was a median of two production slots per month from March 2021 to October 2021. All slots were filled.
Cecilia BrownMyeloma | August 14, 2023
The bispecific antibody received Breakthrough Therapy Designation from the FDA in November 2022.
Cecilia BrownMyeloma | August 14, 2023
There was no significant difference in the number of mutations present at diagnosis between the two groups of patients.
Cecilia BrownMyeloma | August 14, 2023
The researchers used a cumulative deficit approach to calculate a frailty index score at diagnosis and at landmark intervals.
Cecilia BrownMyeloma | August 10, 2023
It is approved as a weekly or biweekly subcutaneous injection after an initial step-up phase.
Cecilia BrownMyeloma | August 9, 2023
More than one-quarter of the patients required a dose reduction due to adverse events.
Leah SherwoodMyeloma | August 2, 2023
The US FDA and NMPA have approved IND applications for LBL-034 for the treatment of relapsed or refractory multiple myeloma.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Shambavi Richard, MDMyeloma | July 17, 2023
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
Claudio Cerchione, MD, PhDMyeloma | July 5, 2023
Dr. Cerchione discusses the importance of ensuring adequate representation in multiple myeloma clinical trials.
Editorial Board